Repository logo
 

Framingham vascular age is associated with worse cognitive performance in the middle-aged and elderly.

Accepted version
Peer-reviewed

No Thumbnail Available

Type

Article

Change log

Authors

Badran, Abdul 
Hollocks, Matthew J 
Brookes, Rebecca L 
Morris, Robin G 
Markus, Hugh S 

Abstract

"Normal" age-related cognitive decline has been associated with cardiovascular risk factors. Framingham Vascular Age is age-normed cardiovascular risk which may help communicate risk to patients and identify those at relatively higher risk. We aim to assess the association between Framingham Vascular Age and cognition. 346 "healthy" participants (57±10 years) without neuropsychiatric disorders or clinical manifestations of cardiovascular disease were studied. Cognition was evaluated using the Brief Memory and Executive Test and Framingham Vascular Age was calculated. The association between Framingham Vascular Age and cognitive performance was determined through General Linear Models to control for covariates. Framingham Vascular age was associated with poorer Memory and Executive Function/Processing Speed indices (p= 0.019 and p<0.001, respectively). We conclude Framingham Vascular Age is associated with worse Executive Function/Processing Speed and Memory. Vascular Age may help identify patients at higher risk of age-related cognitive decline with implications for communicating the morbidity associated with cardiovascular risk.

Description

Keywords

Age-related cognitive decline, Framingham, brief memory and executive test, screening, vascular age

Journal Title

Neuropsychol Dev Cogn B Aging Neuropsychol Cogn

Conference Name

Journal ISSN

1382-5585
1744-4128

Volume Title

26

Publisher

Taylor & Francis
Sponsorship
Stroke Association (TSA 2010/08)
British Heart Foundation (None)
This work was supported by the Stroke Association under Grant TSA 2010/08; British Heart Foundation under Grant PG/13/30/30005; and Stroke Association/British Heart Foundation Programme under Grant TSA BHF 2010/01. Hugh Markus is supported by a National Institute for Health Research Senior Investigator award and his work is supported by the Cambridge University Hospitals Trust National Institute for Health Research Comprehensive Biomedical Research Centre.